YUFE Bio™ unifies disease biology, multi-omic data, and translational feasibility into one decision engine — to discover, reposition, and rescue therapeutic candidates that are biologically rational and pharmacologically achievable.
Drug development is the most expensive guess in science. YUFE Bio™ turns that guess into a prioritized, feasibility-screened decision — so time and capital go to the candidates most likely to reach patients.
By starting from approved-safety compounds and existing biology — and filtering every candidate through exposure, BBB, PK/PD, and target engagement before the bench — YUFE Bio™ removes the candidates that would have failed for visible reasons, and concentrates spend on the ones that can.
Multi-omic disease data maps the pathways driving the indication.
Candidate interventions are identified and scored across existing chemical and biological space.
Exposure, BBB, PK/PD, target engagement, and safety are evaluated.
A prioritized, transparent shortlist with feature-level attribution.
YUFE Bio™ connects the parts of translational research usually handled in isolation — disease biology, drug mechanism, patient stratification, and real-world feasibility — into a single, explainable framework.
Identify and prioritize candidate biomarkers, pathways, and therapeutic interventions from existing chemical and biological space — focusing effort on the most promising directions first.
Match approved compounds to new indications by their capacity to reverse disease biology — surfacing candidates that already carry established safety and pharmacology.
Give shelved or clinically failed assets a second life. The platform distinguishes likely efficacy-driven failures — candidates for biomarker-defined rescue — from those that failed for other reasons, repositioning them toward secondary indications.
An externally validated, locked risk model stratifies patients by tumor biology — replicating across independent cohorts and across both RNA-seq and microarray platforms.
Derive and validate proteomic and phosphoproteomic panels that capture the active, functional state of disease biology — where transcriptomic signal alone falls short.
Every prediction arrives with feature-level attribution — so prioritization is transparent, defensible, and ready for grant, patent, and experimental planning.
Aggressive, recurrent, and metastatic disease is driven by the tumor's active, functional state — not just by which genes are switched on.
Post-translational modifications — phosphorylation and the signaling state of the proteome — capture which pathways are actually firing, how a tumor rewires under treatment pressure, and why it returns more aggressive at recurrence. This is the layer transcriptomic-only analysis cannot see, and where conventional RNA-based platforms miss the drivers that matter most.
Black-box rankings are hard to trust and harder to act on. YUFE Bio™ attaches transparent, feature-level attribution to every prediction — so you can see what drove each result, challenge it, and defend it in front of a board or a reviewer.
Representative illustration of how factors contribute to a candidate's prioritization.
Validation reflects independent cohorts and same-endpoint holdouts, with train and test endpoints kept strictly separate. These are external, leakage-controlled results.
Externally validated predictive and prognostic performance, supporting research-grade prioritization and experimental follow-up.
How YUFE Bio™ compares to conventional AI drug platforms on the dimensions that decide whether a candidate can actually reach patients.
| Dimension | YUFE Bio™ | Conventional AI drug platforms |
|---|---|---|
| Translational feasibility | Built-in — exposure, BBB, PK/PD, and target engagement scored from the start | Biology-only ranking; feasibility assessed later, if at all |
| Validation | External & leakage-controlled — independent cohorts, endpoints kept separate | Often in-sample or leaderboard metrics presented as validation |
| Explainability | Feature-level attribution on every prediction | Black-box scores with limited or no attribution |
| Data depth | Genomic to phosphoproteomic — captures the active, functional disease state | Frequently transcriptomic-only, missing post-translational signal |
| Asset rescue | Distinguishes rescuable failures and repositions shelved assets by biomarker-defined subgroups | Rarely addresses failed or shelved clinical assets |
| Deliverable | A decision, not a list — prioritized, explained, experiment-ready | Headline rankings without a path to the bench |
From a focused discovery scan to an end-to-end translational strategy, every engagement begins under mutual NDA and delivers prioritized, explainable, experiment-ready findings.
|
YUFE Discovery
$6,500 – $9,500
1–2 weeks
|
Recommended
YUFE Precision Repurposing
$18,000 – $28,000
3–5 weeks
|
YUFE Translational Strategy
$45,000+
6–12 weeks
|
|
|---|---|---|---|
| Prioritized candidate shortlist (drugs, biomarkers, pathways) | |||
| Disease pathway signature interpretation | |||
| Mechanistic rationale & summary report | |||
| Full multi-omic signature analysis | — | ||
| Translational readiness scoring per candidate | — | ||
| Asset-rescue analysis with biomarker-defined strategies | — | ||
| Feature-level attribution (explainability) | — | ||
| Deep multi-omic integration (proteome & phosphoproteome) | — | — | |
| Resistance modeling & combination predictions | — | — | |
| Dedicated program model — your data, firewalled | — | — | |
| Patent-support technical evidence map | — | — | |
| Executive strategy briefing & program report | — | — | |
| Request scope | Request scope | Request scope |
Representative analyses showing the type of question YUFE Bio™ addresses and the form its outputs take.
From the indication's disrupted pathway signature, the platform screens approved compounds and ranks them by biological reversal and translational feasibility.
A previously deprioritized compound is re-examined for a biomarker-defined patient subgroup where its mechanism is most likely to succeed.
An externally validated risk model stratifies a cohort by tumor biology, replicated across independent cohorts and measurement platforms.
YUFE Bio™ is open to investment and strategic partnership conversations with groups building in precision oncology and computational drug development.
Detailed materials, validation evidence, and IP overview are available to qualified investors and partners under NDA.
Start a conversationYUFE Bio™ exists to close a costly gap in translational medicine: promising biology fails when it is never evaluated through a complete translational lens. Computational promise means little unless a candidate can actually reach patients.
The platform unites physics-informed, biologically-constrained modeling with multi-omic interpretation, drug-repurposing and asset-rescue logic, and explainable AI — so research teams can move faster on the candidates that matter, and walk away from the ones that don't.
Tell us about your target, indication, asset, or program. Every engagement begins under mutual NDA.